Synovial Anti Cyclic Citrullinated Peptide Antibodies in Comparison with Serum Antibodies in Early and Late Rheumatoid Arthritis
Fortune Journal of Rheumatology · 2020
DOI: 10.26502/fjr.26880019 ↗Kurz gefasst
Fachartikel in der Zeitschrift Fortune Journal of Rheumatology, 2020. Verfasst von Kamila Hashemzadeh und 3 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Aim
The study objective was to evaluate the diagnostic value of synovial fluid anti cyclic citrullinated peptide (sf-anti CCP) in comparison to serum anti CCP (s-anti CCP) in early and late rheumatoid arthritis and to clarify its correlation with disease activity.
Methods
In this cross-sectional study a total of 45 patients aged between 18 and 70 years with rheumatoid arthritis (RA) according to the ACR criteria were enrolled. Twenty six patients had a disease duration of more than 2 years (late RA) whereas 19 cases were referred to as early RA (
Zitieren
APA
Hashemzadeh, K., Saghafi, M., Khajedaluee, M., & Sahebari, M. (2020). Synovial Anti Cyclic Citrullinated Peptide Antibodies in Comparison with Serum Antibodies in Early and Late Rheumatoid Arthritis. Fortune Journal of Rheumatology. https://doi.org/10.26502/fjr.26880019
Vancouver
Hashemzadeh K, Saghafi M, Khajedaluee M, Sahebari M. Synovial Anti Cyclic Citrullinated Peptide Antibodies in Comparison with Serum Antibodies in Early and Late Rheumatoid Arthritis. Fortune Journal of Rheumatology. 2020. doi:10.26502/fjr.26880019
BibTeX
@article{Hashemzadeh2020,
author = {Hashemzadeh, Kamila and Saghafi, Massoud and Khajedaluee, Mohammad and Sahebari, Maryam},
title = {Synovial Anti Cyclic Citrullinated Peptide Antibodies in Comparison with Serum Antibodies in Early and Late Rheumatoid Arthritis},
journal = {Fortune Journal of Rheumatology},
year = {2020},
doi = {10.26502/fjr.26880019}
}
EUVIMED